
Context Therapeutics Investor Relations Material
Latest events

Q1 2025
6 Aug, 2025

Q4 2024
19 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Context Therapeutics Inc
Access all reports
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
CNTX
Country
🇺🇸 United States